UPDATE: Novo Nordisk Says Primary Endpoint, Rate Of Overall Symptomatic Hypoglycaemia In Maintenance Period Of 36 Weeks Which Was Tested For Superiority, Was Numerically Lower But Not Statistically Significant Versus Insulin Glargine U300